According to report by Persistence Market Research, “Global Market Study on Active Pharmaceutical Ingredient (API): Industry Analysis and Forecast 2015-2020”, the market reached the value of US$ 127Bn at the end of 2014. The increased demand for pharmaceutical drugs owing to the rising ageing population, increasing incidences of chronic illnesses and infectious diseases is major factor fueling the global API market.
The growing prevalence of chronic illnesses such as diabetes, cancer, neurological, and cardiovascular
diseases is a major driver in the global market. Manufacturers are making the shift from small molecules
manufacturing to biologic drugs. This is resulting in increased opportunities for contract manufacturing
companies in the global market. The blockbuster drugs being taken off the shelf as well as in-house
manufacturing of biologics owing to intellectual property concerns are major challenges in the global API
In terms of manufacturing process, the global market is segmented into captive manufacturing and
contrast manufacturing. On the basis of product type, the market is segmented into synthetic chemical
API and biological API. The biological API segment is the fastest growing in the global API market with
a high growth rate of 8% through the forecast period of 2015-2020.
In terms of drug type, the market is segmented into branded prescription drugs, generic prescription
drugs, and OTC prescription drugs. The branded prescription drugs segment is the leading segment in the
global market owing to aggressive marketing by the players. The generic prescription drugs segment is
the fastest growing segment in the global API market through the forecast period 2015-2020.
In terms of therapeutic area, the market is segmented into cardiovascular disorders, metabolic disorders,
neurological disorders, oncology, musculoskeletal disorders, NSAIDs, and other therapeutics uses. The
cardiovascular disorders and NSAIDs segments collectively account for the major share in the global
In terms of region, the global API market is segmented into North America, Europe, Asia Pacific, and
Rest of the World. North America is the largest market segment owing to the highest consumption and
imports of API across the globe. India and China are the leading suppliers of API to North America owing
to low cost of labor and production. Asia Pacific is the second largest market region owing to low cost of
production facilities and labor, along with the presence of large number of global and domestic players in
the region, especially in China and India.
Key players in the global API market include WuXi AppTec, Allergan Plc., Pfizer, Inc., Sandoz (Novartis
AG), Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, BASF SE, Lonza Group, Boehringer
Ingelheim GmbH, Cambrex Corporation, and Mylan N.V. Leading players in the market are focusing
towards increasing their product portfolio and higher market penetration.
To get more information: